从非洲之角抵达欧洲的患者中耐多药结核分枝杆菌聚集性病例:一项分子流行病学研究
2016至2017年,7个欧洲国家诊断29例耐多药结核病患者,均来自非洲之角或苏丹,所有分离株间SNP差异≤2个,提示共同来源。另发现29例MIRU-VNTR关联的既往病例,但与本次暴发株SNP差异>5个,全部58株共享tlyA突变。作者推测传播可能发生在抵达欧洲途中,tlyA突变为耐药相关系统发育标记。
要点
- 2016年2月12日至2017年4月19日,7个欧洲国家报告29例耐多药结核病,均源自非洲之角或苏丹。
- 全部29例暴发株间SNP差异≤2个,另29例MIRU-VNTR关联既往株与暴发株SNP差异>5个。
- 全部58株共享tlyA突变,作者假设其为耐药突变和系统发育标记,属结核分枝杆菌狭义种中首例。
核心结论
- 数据提示源病例与在索马里北部或吉布提循环的结核分枝杆菌克隆相关,传播可能发生在抵达欧洲途中。
- 作者假设共享的tlyA突变为耐药突变和系统发育标记,是结核分枝杆菌狭义种中首例此类标记。
研究设计与样本
- 分子流行病学研究,2016年4月29日和5月30日瑞士和德国国家分枝杆菌参考实验室在4例患者诊断为耐多药结核病后独立启动暴发调查。
- 前瞻性定义暴发病例:24位点MIRU-VNTR图谱、对异烟肼、利福平、乙胺丁醇、吡嗪酰胺和卷曲霉素的表型耐药及相应耐药突变。
- 对所有结核分枝杆菌分离株进行全基因组测序,以5个单核苷酸多态性(SNP)为阈值进行聚类。
- 从欧洲疾病预防控制中心汇总来源国的流行病学数据。
主要发现
- 2016年2月12日至2017年4月19日,7个欧洲国家诊断29例耐多药结核病患者,全部源自非洲之角或苏丹,所有分离株间SNP差异≤2个。
- 22例(76%)患者报告旅行路线,路线间存在明确的时空重叠。
- 另发现29例来自非洲之角的MIRU-VNTR关联病例早于本次暴发,但所有分离株与暴发株SNP差异>5个。
- 全部58株分离株共享卷曲霉素耐药相关的tlyA突变。
关键数值与推荐
- 暴发病例定义:24位点MIRU-VNTR图谱、对异烟肼、利福平、乙胺丁醇、吡嗪酰胺和卷曲霉素表型耐药及相应耐药突变。
- 聚类阈值:5个SNP。
- 暴发株间SNP差异≤2个;MIRU-VNTR关联既往株与暴发株SNP差异>5个。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The risk of tuberculosis outbreaks among people fleeing hardship for refuge in Europe is heightened. We describe the cross-border European response to an outbreak of multidrug-resistant tuberculosis among patients from the Horn of Africa and Sudan. METHODS: On April 29 and May 30, 2016, the Swiss and German National Mycobacterial Reference Laboratories independently triggered an outbreak investigation after four patients were diagnosed with multidrug-resistant tuberculosis. In this molecular epidemiological study, we prospectively defined outbreak cases with 24-locus mycobacterial interspersed repetitive unit-variable number tandem repeat (MIRU-VNTR) profiles; phenotypic resistance to isoniazid, rifampicin, ethambutol, pyrazinamide, and capreomycin; and corresponding drug resistance mutations. We whole-genome sequenced all Mycobacterium tuberculosis isolates and clustered them using a threshold of five single nucleotide polymorphisms (SNPs). We collated epidemiological data from host countries from the European Centre for Disease Prevention and Control. FINDINGS: Between Feb 12, 2016, and April 19, 2017, 29 patients were diagnosed with multidrug-resistant tuberculosis in seven European countries. All originated from the Horn of Africa or Sudan, with all isolates two SNPs or fewer apart. 22 (76%) patients reported their travel routes, with clear spatiotemporal overlap between routes. We identified a further 29 MIRU-VNTR-linked cases from the Horn of Africa that predated the outbreak, but all were more than five SNPs from the outbreak. However all 58 isolates shared a capreomycin resistance-associated tlyA mutation. INTERPRETATION: Our data suggest that source cases are linked to an M tuberculosis clone circulating in northern Somalia or Djibouti and that transmission probably occurred en route before arrival in Europe. We hypothesise that the shared mutation of tlyA is a drug resistance mutation and phylogenetic marker, the first of its kind in M tuberculosis sensu stricto. FUNDING: The Swiss Federal Office of Public Health, the University of Zurich, the Wellcome Trust, National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), the Medical Research Council, BELTA-TBnet, the European Union, the German Center for Infection Research, and Leibniz Science Campus Evolutionary Medicine of the Lung (EvoLUNG).
引用
- Walker TM, Merker M, Knoblauch AM, et al. A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. Lancet Infect Dis. 2018. PMID: 29326013. doi:10.1016/S1473-3099(18)30004-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。